Plain-English translation of NCT07192120 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 1/2 — A combined trial that checks safety and dosing while also starting to look at whether the treatment works.
This is a first-in-human trial testing a new cancer drug called MHB048C. The study has two parts: first, researchers will gradually increase doses to find the safest and most effective amount, then test that dose in more patients with advanced solid tumors or metastatic prostate cancer. The medication is given by injection.
Standard cancer treatments don't work for everyone, and some patients develop resistance or can't tolerate existing options. This medication is being tested to offer a new treatment choice for people with advanced cancers that have stopped responding to conventional therapy.
You likely qualify if…
You likely don't qualify if…
You will receive injections of the medication at a medical center as part of either the dose-escalation phase (where doses gradually increase to find the right level) or the dose-expansion phase (where more patients receive the best dose found). You'll have regular visits for blood tests, imaging scans, and check-ups to monitor how well the treatment works and watch for side effects. The study is designed to last several months, though the exact duration depends on how you respond to treatment.
AI-generated summary from trial data · Jun 18, 2026 · Not medical advice
China